Pharco Pharmaceuticals

pharco.org

Pharco Pharmaceuticals is the mother company of Pharco group, founded by Dr. Hassan Abbas Helmy in 1983. operating in the pharmaceutical field for development, manufacturing, marketing, distributing and exporting of a comprehensive array of generics and branded generic drugs under the name of Pharco, along with a rising number of licensed pharmaceutical products. Pharco Corp. is the largest manufacturer of pharmaceuticals in the MENA region, focused on research, formulation, manufacturing and commercialization of pharmaceutical products. Today Pharco Corp. employs over 8,000 employees, and has over 650 Million packs produced in 2017 — ranking as the leader in the Egyptian pharmaceutical market. Pharco also exports to 53 countries around the world. Pharco works towards one goal is to provide highly effective and safe pharmaceutical products to patients at an affordable price.a

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BUSINESS INSIGHTS

NANOLOGY PUBLISHES REVIEW ARTICLE OF PRECLINICAL AND CLINICAL RESEARCH SUPPORTING LSAM-DTX

NanOlogy | September 21, 2022

news image

NanOlogy LLC, a clinical-stage interventional oncology drug company, announced that a review article of preclinical and clinical research supporting its investigational drug, large surface area microparticle docetaxel has been published in Drug Delivery and Translational Research. The review article entitled Local administration of large surface area microparticle docetaxel to solid carcinomas induces direct cytotoxicity and immune‑mediated tumoricidal effects: preclinical and cli...

Read More

PHARMA TECH

APOLLOMICS INC., A LATE-STAGE CLINICAL BIOPHARMACEUTICAL COMPANY TO BE LISTED ON NASDAQ THROUGH BUSINESS COMBINATION

Apollomics, Inc. | September 15, 2022

news image

Apollomics Inc. a late-stage clinical biopharmaceutical company, and Maxpro Capital Acquisition Corp. announced a definitive agreement for a business combination that would result in Apollomics becoming a publicly traded company on the Nasdaq Global Market. The business combination is expected to close in the first quarter of 2023 and Apollomics is expected to be listed on Nasdaq under the ticker symbol “APLM.” Apollomics’ broad pipeline of drug candidates includ...

Read More

BUSINESS INSIGHTS

AGILENT ANNOUNCES THE INNOVATIVE SEAHORSE XF PRO ANALYZER

Agilent Technologies Inc. | January 25, 2022

news image

Agilent Technologies Inc. announced the release of the Agilent Seahorse XF Pro Analyzer, featuring new pharma-oriented workflow solutions incorporating advanced experimental design and analysis tools. With enhanced performance, more robust and efficient workflows, and an optimized user experience, the XF Pro enables operators at any skill level to access the most advanced cellular metabolism analysis technology for understanding cellular fate, fitness, and function. Preclinical th...

Read More

BUSINESS INSIGHTS

SANDOZ TARGETS GROWTH OPPORTUNITIES IN RESPIRATORY AND COMPLEX GENERICS THROUGH ACQUISITION OF RESPIRATORY DEVICE COMPANY COALESCE

Novartis Pharma AG | March 14, 2022

news image

Sandoz, a Novartis division, announced that it has successfully acquired the UK-based medical and drug delivery device development company, Coalesce Product Development Limited. Through this deal, Sandoz has acquired the significant capabilities and assets of Coalesce, which will help it build on its existing portfolio of respiratory medicines and further improve patient access to these high-quality, complex therapies. “Respiratory and co...

Read More
news image

BUSINESS INSIGHTS

NANOLOGY PUBLISHES REVIEW ARTICLE OF PRECLINICAL AND CLINICAL RESEARCH SUPPORTING LSAM-DTX

NanOlogy | September 21, 2022

NanOlogy LLC, a clinical-stage interventional oncology drug company, announced that a review article of preclinical and clinical research supporting its investigational drug, large surface area microparticle docetaxel has been published in Drug Delivery and Translational Research. The review article entitled Local administration of large surface area microparticle docetaxel to solid carcinomas induces direct cytotoxicity and immune‑mediated tumoricidal effects: preclinical and cli...

Read More
news image

PHARMA TECH

APOLLOMICS INC., A LATE-STAGE CLINICAL BIOPHARMACEUTICAL COMPANY TO BE LISTED ON NASDAQ THROUGH BUSINESS COMBINATION

Apollomics, Inc. | September 15, 2022

Apollomics Inc. a late-stage clinical biopharmaceutical company, and Maxpro Capital Acquisition Corp. announced a definitive agreement for a business combination that would result in Apollomics becoming a publicly traded company on the Nasdaq Global Market. The business combination is expected to close in the first quarter of 2023 and Apollomics is expected to be listed on Nasdaq under the ticker symbol “APLM.” Apollomics’ broad pipeline of drug candidates includ...

Read More
news image

BUSINESS INSIGHTS

AGILENT ANNOUNCES THE INNOVATIVE SEAHORSE XF PRO ANALYZER

Agilent Technologies Inc. | January 25, 2022

Agilent Technologies Inc. announced the release of the Agilent Seahorse XF Pro Analyzer, featuring new pharma-oriented workflow solutions incorporating advanced experimental design and analysis tools. With enhanced performance, more robust and efficient workflows, and an optimized user experience, the XF Pro enables operators at any skill level to access the most advanced cellular metabolism analysis technology for understanding cellular fate, fitness, and function. Preclinical th...

Read More
news image

BUSINESS INSIGHTS

SANDOZ TARGETS GROWTH OPPORTUNITIES IN RESPIRATORY AND COMPLEX GENERICS THROUGH ACQUISITION OF RESPIRATORY DEVICE COMPANY COALESCE

Novartis Pharma AG | March 14, 2022

Sandoz, a Novartis division, announced that it has successfully acquired the UK-based medical and drug delivery device development company, Coalesce Product Development Limited. Through this deal, Sandoz has acquired the significant capabilities and assets of Coalesce, which will help it build on its existing portfolio of respiratory medicines and further improve patient access to these high-quality, complex therapies. “Respiratory and co...

Read More